公开(公告)号：US20230212250A1

公开(公告)日：2023-07-06

申请号：US17609731

申请日：2020-05-11

申请人： UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

发明人： Stefan Franz Thomas WEISS ,  Katelyn CUTTLER ,  Tyrone Chad OTGAAR ,  Eloise VAN DER MERWE ,  Monique J. BIGNOUX

IPC分类号： C07K14/47 ,  C07K14/705 ,  C07K14/78

CPC分类号： C07K14/4711 ,  C07K14/705 ,  C07K14/78

摘要： This disclosure relates to a method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein in a target cell of a human or animal subject having Alzheimer's Disease (AD). The disclosure extends to use of biopharmaceutical agents including (i). 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof, or (ii). a transfecting agent for the expression of LRP/LR, for use in treating Alzheimer's Disease (AD).

公开(公告)号：US20210277084A1

公开(公告)日：2021-09-09

申请号：US17258217

申请日：2019-07-08

申请人： UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

发明人： Stefan Franz Thomas WEISS ,  Tyrone Chad OTGAAR ,  Eloise VAN DER MERWE ,  Martin BERNERT ,  Gavin MORRIS

IPC分类号： C07K14/705 ,  A61P3/04 ,  A61P5/50

摘要： A biopharmaceutical agent including a 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in treatment and/or prevention of atherosclerosis and/or obesity and/or insulin resistance and/or diabetes. The biopharmaceutical agent may be encapsulated by functionalized or non-functionalized nanoparticles, and further may be formulated to include a carrier to provide a pharmaceutical composition for parental or non-parental administration. In use, the biopharmaceutical agent reduces lipid content in target cells. Also, a method of decreasing lipid concentration in a target cell of a human or animal subject.

公开(公告)号：US20200326334A1

公开(公告)日：2020-10-15

申请号：US16772699

申请日：2018-12-14

申请人： University of the Witwatersrand, Johannesburg

发明人： Boitelo Teresa LETSOLO ,  Martin BERNERT ,  Stefan Franz Thomas WEISS

IPC分类号： G01N33/535 ,  C12Q1/48 ,  G01N33/553

摘要： The invention relates to methods for producing gold nanoparticles functionalised with a telomerase substrate, or a linker nucleic acid having a region complementary to a nucleic acid comprising a telomerase substrate, for use in detecting telomerase activity. Functionalised gold nanoparticle solutions and functionalised gold nanoparticles obtained using the method are also provided for. The invention further relates to a functionalised gold nanoparticle complex, comprising gold nanoparticles coupled to a linker nucleic acid which is hybridised to a nucleic acid comprising a telomerase substrate. Telomerase assays using the functionalised gold nanoparticles or functionalised gold nanoparticle complexes of the invention and kits for detecting telomerase activity in a cell, comprising the functionalised gold nanoparticles or functionalised gold nanoparticle complexes of the invention are also provided for.

公开(公告)号：US20220160824A1

公开(公告)日：2022-05-26

申请号：US17298415

申请日：2019-11-28

申请人： UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

发明人： Stefan Franz Thomas WEISS ,  Eloise VAN DER MERWE ,  Katelyn CUTTLER ,  Monique BIGNOUX ,  Jessica BURNS

IPC分类号： A61K38/17 ,  A61K31/198 ,  A61K31/137 ,  A61K45/06 ,  A61P25/16

摘要： LRP/LR for use in the treatment and/or prevention of Parkinson's disease (PD). Pharmaceutical compositions comprising LRP/LR for use in the treatment of Parkinson's Disease (PD), and a method of maintaining concentration levels of dopamine within a human or animal body.